MREO Stock Overview
A biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Mereo BioPharma Group plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$3.47 |
52 Week High | US$4.36 |
52 Week Low | US$1.07 |
Beta | 0.71 |
1 Month Change | 14.52% |
3 Month Change | 8.78% |
1 Year Change | 166.92% |
3 Year Change | 7.43% |
5 Year Change | 21.33% |
Change since IPO | -46.62% |
Recent News & Updates
Recent updates
Is Mereo BioPharma Group (NASDAQ:MREO) Weighed On By Its Debt Load?
Apr 07Is Mereo BioPharma Group (NASDAQ:MREO) Using Debt Sensibly?
Nov 25Mereo stock rises 12% on FDA fast-track status for lung disease drug alvelestat
Oct 17Rubric Capital boosts Mereo BioPharma board nominees slate to five
Oct 03Mereo BioPharma: An Activist Pressure With A Potentially Significant Upside
Sep 22Mereo activist investor Rubric asks board again to hold general meeting, nominate directors
Sep 14Mereo BioPharma Group regains compliance with Nasdaq's listing rule
Jul 05Mereo BioPharma: Activist Pressure In A Net-Net Biopharma
Jun 17Mereo BioPharma: Anti-TIGIT Developer In Mid-Stage Development
Dec 08Mereo BioPharma and Cancer Focus Fund ink partnership for ovarian cancer study
Apr 30Shareholder Returns
MREO | US Biotechs | US Market | |
---|---|---|---|
7D | 4.2% | 2.3% | 1.2% |
1Y | 166.9% | 6.8% | 20.8% |
Return vs Industry: MREO exceeded the US Biotechs industry which returned 8.3% over the past year.
Return vs Market: MREO exceeded the US Market which returned 22.5% over the past year.
Price Volatility
MREO volatility | |
---|---|
MREO Average Weekly Movement | 9.4% |
Biotechs Industry Average Movement | 10.5% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.7% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: MREO's share price has been volatile over the past 3 months.
Volatility Over Time: MREO's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 33 | Denise Scots-Knight | www.mereobiopharma.com |
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials.
Mereo BioPharma Group plc Fundamentals Summary
MREO fundamental statistics | |
---|---|
Market cap | US$485.89m |
Earnings (TTM) | -US$26.34m |
Revenue (TTM) | US$10.00m |
48.6x
P/S Ratio-18.4x
P/E RatioIs MREO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MREO income statement (TTM) | |
---|---|
Revenue | US$10.00m |
Cost of Revenue | US$2.92m |
Gross Profit | US$7.08m |
Other Expenses | US$33.42m |
Earnings | -US$26.34m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.19 |
Gross Margin | 70.79% |
Net Profit Margin | -263.41% |
Debt/Equity Ratio | 10.8% |
How did MREO perform over the long term?
See historical performance and comparison